Cherian SV, Kaur S, Karanth S, Xian JZ, Estrada-Y-Martin RM. Diagnostic yield of electromagnetic navigational bronchoscopy: a safety net community-based hospital experience in the United States. Ann Thorac Med. 2021 Jan;16(1):102-9. doi: 10.4103/atm.ATM_388_20
Cainzos-Achirica M, Bilal U, Al Rifai M, McEvoy JW, Blumenthal RS, Kapoor K, Martinez-Sanchez JM, Comin-Colet J, Pladevall-Vila M, Blaha MJ. Communication issues in nutritional observational research. Prev Med. 2018 Oct;115:76-82. doi: 10.1016/j.ypmed.2018.08.024
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Mueller N, Rojas-Rueda D, Salmon M, Martinez D, Ambros A, Brand C, de Nazelle A, Dons E, Gaupp-Berghausen M, Gerike R, Gotschi T, Iacorossi F, Panis LI, Kahlmeier S, Raser E, Nieuwenhuijsen M, PASTA consortium. Health impact assessment of cycling network expansions in European cities. Prev Med. 2018 Apr;109:62-70. doi: 10.1016/j.ypmed.2017.12.011
Karanth SS, Lairson DR, Huang D, Savas LS, Vernon SW, Fernandez ME. The cost of implementing two small media interventions to promote HPV vaccination. Prev Med. 2017 Jun;99:277-81. doi: 10.1016/j.ypmed.2017.03.002
Raspa M, Sacco P, Candrilli SD, Bishop E, Petrillo J. Validity of a condition specific outcome measure for fragile X syndrome: the Aberrant Behaviour Checklist-utility index. J Intellect Disabil Res. 2016 Sep;60(9):844-55. doi: 10.1111/jir.12264
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Bayer AM, Danysh HE, Garvich M, Gonzalvez G, Checkley W, Alvarez M, Gilman RH. An unforgettable event: a qualitative study of the 1997-98 El Niño in northern Peru. Disasters. 2014 Apr;38(2):351-74. doi: 10.1111/disa.12046
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Viera AJ, Sheridan SL, Edwards T, Soliman EZ, Harris R, Furberg CD. Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Prev Med. 2011 Jan;52(1):10-5. doi: 10.1016/j.ypmed.2010.09.016
Hahn EJ, Rayens MK, Chirila C, Riker CA, Paul TP, Warnick TA. Effectiveness of a quit and win contest with a low-income population. Prev Med. 2004 Sep 1;39(3):543-50.
Feldman HA, Johannes CB, Derby CA, Kleinman KP, Mohr BA, Araujo AB, McKinlay JB. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts Male Aging Study. Prev Med. 2000 Apr 1;30(4):328-38.
Rothman KJ. The proportion of cancer attributable to alcohol-consumption. Prev Med. 1980 Mar 1;9(2):174-9.